Giuseppe Carrà

Giuseppe Carrà

CURRICULUM VITAE

Giuseppe Carrà is an Associate Professor of Psychiatry at University of Milan Bicocca and a Research Associate at the Division of Psychiatry, University College of London

Giuseppe extensively researched in the addiction field in the last 25 years, with particular focus on comorbid severe mental illnesses and substance abuse. 

Author of over 160 papers in scientific, peer-reviewed journals, Giuseppe co-edited the “Textbook of Addiction Treatment: International Perspectives” , Springer-Nature 2015.

Clinically he works as the Medical Director of a large Mental Health and Addiction Department in Milan (I).

  • July 1st 2018-present: Psychiatric Services Director. Edoardo Bassini and Sesto San Giovanni Hospitals (MI).
  • September 1st 2018-present: Mental Health and Addiction Department Director. North Milan Community Health and Social Care Trust. 

PERSONAL DETAILS

  • UK General Medical Council Full Registration No 6135867
  • September 5th 2005: UK Specialist Register: General Psychiatry

July 24th 2018: Qualified Full Professor in Psychiatry

September 2004-December 2016: Research Fellow. Division of Psychiatry, University College of London.

December 2016-present: Research Associate, Division of Psychiatry, University College of London.

RESEARCH INTERESTS

Social and Community Psychiatry. Addiction Psychiatry. Physical Health in people with mental disorders. E-Health in mental disorders. Psychiatric Epidemiology. Psychoeducational Interventions in severe mental disorders. 

GOVERNMENTAL AND INSTITUTIONAL APPOINTMENTS

  • Member of the panel of independent experts assisting European Commission at Directorate General of justice, freedom and security in the priority field “Prevent drug consumption and inform the public” July ‘07- June ‘10.
  • Seconded to the Italian Department of Health for analysis and implementation of the 2007 National Report on Drug Abuse – April-May ’08
  • Member of experts’ panel assisting the International Bureau of the Federal Ministry of Education and Research at the Project Management Agency c/o German Aerospace Center (DLR) 2010-present
  • Member of experts’ panel assisting European Commission at the Directorate for Health and Consumers and at the Directorate General of justice, freedom and security and assessing project proposals under Drug Prevention and Information Proposals (DPIP) call for action grants 2008, 2009/2010, 2011/2012, 2013.
  • Member of experts’ panel assisting the United Nations Office on Drugs and Crime (UNODC) in reviewing evidence on Voluntary-based or compulsory drug dependence treatment – October 2009.
  • Member of the peer review group for Treatnet II Quality Standards of Care Project at the United Nations Office on Drugs and Crime (UNODC) – October 2011
  • Member of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) key experts group aimed at identifying current research gaps in the treatment of drug addiction. October 2012
  • Member of experts’ panel assisting the European Commission for the call ‘Personalised Medicine’ (H2020-SC1-2016-2017), 2016
  • Ad-hoc reviewer for the report “NOVEL TECHNOLOGICAL APPROACH FOR SUBSTANCE ABUSE DISORDERS” produced by the European Brain Council and commissioned by the Science and Technology Options Assessment (STOA) Panel at the European Parliament, 2016-2017
  • Member of the University of Milan Bicocca committee for research promotion, support and valorisation, March 2016-September 2019
  • Ad-hoc reviewer for the National Institute for Health Research (UK), Evaluation, Trials and Studies (NETS) programme, 2017-today
  • Member of the expert panel assisting the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) for the publication of the EMCDDA Report “Health and Social Responses to Drug Problems in Europe”, 2017
  • Member of the expert panel assisting the United Nations Office on Drugs and Crime (UNODC) for the report “Treatment and Care of People with Drug Use Disorders in Contact with the Criminal Justice System: Alternatives to Conviction or Punishment”, October 2017
  • Ad-hoc reviewer for the Chief Medical Officer Directorate, Chief Scientist Office Division The Scottish Government, October 2018 
  • Ad-hoc reviewer for the Ireland Health Research Board (HRB), January 2019 
  • Expert in Healthcare Delivery Systems, Social Media and Mental Health for the World Economic Forum Expert Network, February 2019 
  • Ad-hoc reviewer for the American Society of Addiction Medicine (ASAM) Clinical Practice Guideline on Alcohol Withdrawal Management, September 2019
  • Ad-hoc reviewer for the United Nations Office on Drugs and Crime (UNODC) Universal Treatment Curriculum (UTC) “Alternatives to Incarceration”, October 2019.
  • Member of the expert panel assisting the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) for the updates to the EMCDDA Best practice portal, 2019
  • Member of the expert panel assisting the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) for the assessment of the risks posed by New Psychoactive Substances, January 2020- December 2022.
  • Member of the expert panel assisting the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) for the updates to the EMCDDA briefing on The implications of COVID-19 for people who use drugs (PWUD) and drug service providers http://www.emcdda.europa.eu/publications/topic-overviews/covid-19-and-people-who-use-drugs March 2020

BOARD STATUS

2006: Royal College of Psychiatrists CPD registration

2006: London Regional Panel Section 12 approval

HONOURS AND AWARDS

EDITORIAL ACTIVITIES

  • 2005-present: Member Editorial Board: Substance Abuse. Journal of the Association for Medical Education and Research in Substance Abuse (AMERSA) (Editors: Adam J. Gordon, Marc Galanter).
  • 2007-2009: Member Editorial Board the Open Addiction Journal. Bentham Science Publishers.
  • 2016-present: Consulting Editor for The Journal of General Psychology (Executive Editors: Paula Goolkasian, Andrea M. Karkowski, David Trafimow).
  • 2017-present: Review Editor in Addictive Disorders, Frontiers in Psychiatry https://www.frontiersin.org/journals/psychiatry/sections/addictive-disorders#editorial-board
  • 2018-present: Academic Editor Subject Areas: Medicine and health sciences, Mental health and psychiatry at PLOS ONE https://journals.plos.org/plosone/static/editorial-board 
  • 2019: Handling Editor for the PLOS Medicine Special Issue and PLOS ONE Collection “Substance Use, Misuse and Dependence: Prevention and Treatment”

PUBLICATIONS

Scopus H-index=30

Scopus Author ID: 7003818736 (H-index=30)

ORCID iD: http://orcid.org/0000-0002-6877-6169

Selected publications

  • Carrà G, Crocamo C, Bartoli F, Angermeyer M, Brugha T, Toumi M, Bebbington P. The mediating role of depression in pathways linking positive and negative symptoms in schizophrenia. Psychological Medicine (2020) 50 (4), 566-574. DOI: https://doi.org/10.1017/S0033291719000321 (I.F.=5.641)
  • Carrà G, Crocamo C, Angermeyer M, Brugha T, Toumi M, Bebbington P. Positive and negative symptoms in schizophrenia: A longitudinal analysis using latent variable structural equation modelling. Schizophrenia Research, 2019, 204: 58-64 (I.F.= 3.958)
  • Carrà G, Crocamo C, Bartoli F, Carretta D, Schivalocchi A, Bebbington PE, Clerici M Impact of a mobile e-Health intervention on binge drinking. The D-ARIANNA (Digital – Alcohol RIsk Alertness Notifying Network for Adolescents and young adults) project. Journal of Adolescent Health 58, 5: 520–526, 2016 (I.F.=3.612)
  •  Carrà G, Bartoli F, Crocamo C, Brady KT, Clerici M. Attempted suicide in people with co-occurring bipolar and substance use disorders: Systematic review and meta-analysis. Journal of Affective Disorders 2014, 167:125-135. (IF=3.383)
  • Carrà G, Johnson S, Brugha T, Bebbington P, Angermeyer MC, Heider D, Brugha T, Azorin J, Toumi M. The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe. Findings from the European Schizophrenia Cohort (EuroSC)” European Archives of Psychiatry and Clinical Neurosciences 2012, 7: 607-616. (IF=3.525). Recommended as being of special significance in its field by Michael Soyka from the F1000 Faculty. Soyka M: F1000Prime Recommendation of [Carrà G et al., Eur Arch Psychiatry Clin Neurosci 2012, 262(7):607-16]. In F1000Prime, 22 Jan 2013 DOI: 10.3410/f.717970688.793469240. F1000Prime.com/717970688#eval793469240 .
  •  Carrà G, Sciarini P,Segagni Lusignani G, Clerici M, Montomoli  C, Kessler RC. Do they work across borders? Evaluation of two Measures of Psychological Distress as screening instruments in a non-Anglo-Saxon country. European Psychiatry 2011, 26, 2: 122-127. (IF=3.439)
  •  Carrà G, Johnson S. Variations in rates of comorbid substance use in psychosis between geographical areas and mental health settings in the UK. Social Psychiatry Psychiatric Epidemiology 2009, 44 (6):429-447. (IF= 2.537)
  • Carrà G, Montomoli C, Clerici M, Cazzullo CL. Family interventions for schizophrenia in Italy. Randomised Controlled Trial. European Archives of Psychiatry and Clinical Neuroscience 2007, 257, 1:23-30. (IF= 3.525)
  • El-Guebaly N, Carrà G, Galanter M. (eds.). Textbook of Addiction Treatment: International Perspectives. ISBN: 978-88-470-5321-2 (Print) 978-88-470-5322-9 (Online). SBN 978-88-470-5321-2 ISBN 978-88-470-5322-9 (eBook). ISBN Bundle 978-88-470-5323-6 (print and electronic bundle). DOI 10.1007/978-88-470-5322-9. Springer, Milan Heidelberg New York Dordrecht London, 2015.

See all pubs: https://boa.unimib.it/browse?type=author&order=ASC&rpp=20&authority=rp07358

FURTHER INFO

Please visit https://www.unimib.it/giuseppe-carra